Abstract
Pathological, genetic, biochemical and pharmacological studies support the hypothesis that brain accumulation of oligomeric species of β-amyloid (Aβ) peptides may cause Alzheimers disease (AD). Drugs currently used for the treatment of AD produce limited clinical benefits and do not treat the underlying causes of the disease. In the last 10 years, new therapeutic approaches targeting Aβ have been discovered and developed with the hope of modifying the natural history of the disease. Several active and passive immunotherapy approaches are under investigation in clinical trials with the aim of accelerating Aβ clearance from the brain of the AD patients. The most advanced of these immunological approaches is bapineuzumab, composed of humanized anti-Aβ monoclonal antibodies, that is being tested in two large late-stage trials. Compounds that interfere with proteases regulating Aβ formation from amyloid precursor protein (APP) are also actively pursued. Unfortunately, the most biologically attractive of these proteases, β-secretase, that regulates the first step of the amyloidogenic APP metabolism, was found to be particularly problematic to block and only one compound (CTS21166) has reached clinical testing so far. Conversely, several inhibitors of β-secretase, the protease that regulates the last metabolic step generating Aβ, have been identified, the most advanced being LY-450139 (semagacestat), presently in Phase III clinical development. Compounds that stimulate β-secretase, the enzyme responsible for the nonamyloidogenic metabolism of APP, are also being developed one of them, EHT-0202, has recently started a Phase II study. Furthermore, brain penetrant inhibitors of Aβ aggregation have been identified and one of such compounds, PBT-2, has produced encouraging neuropsychological results in a recently completed Phase II study. With all these anti-Aβ approaches in clinical testing, we will know in few years if the Av hypothesis of AD is correct.
Keywords: β-Amyloid, Alzheimer's disease, active immunotherapy, passive immunotherapy, α-secretase activators, γ-secretase inhibitors, γ-secretase modulators, β-secretase inhibitors
Current Alzheimer Research
Title: Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid
Volume: 7 Issue: 1
Author(s): V. Frisardi, V. Solfrizzi, B. P. Imbimbo, C. Capurso, A. D'Introno, A. M. Colacicco, G. Vendemiale, D. Seripa, A. Pilotto, A. Capurso and F. Panza
Affiliation:
Keywords: β-Amyloid, Alzheimer's disease, active immunotherapy, passive immunotherapy, α-secretase activators, γ-secretase inhibitors, γ-secretase modulators, β-secretase inhibitors
Abstract: Pathological, genetic, biochemical and pharmacological studies support the hypothesis that brain accumulation of oligomeric species of β-amyloid (Aβ) peptides may cause Alzheimers disease (AD). Drugs currently used for the treatment of AD produce limited clinical benefits and do not treat the underlying causes of the disease. In the last 10 years, new therapeutic approaches targeting Aβ have been discovered and developed with the hope of modifying the natural history of the disease. Several active and passive immunotherapy approaches are under investigation in clinical trials with the aim of accelerating Aβ clearance from the brain of the AD patients. The most advanced of these immunological approaches is bapineuzumab, composed of humanized anti-Aβ monoclonal antibodies, that is being tested in two large late-stage trials. Compounds that interfere with proteases regulating Aβ formation from amyloid precursor protein (APP) are also actively pursued. Unfortunately, the most biologically attractive of these proteases, β-secretase, that regulates the first step of the amyloidogenic APP metabolism, was found to be particularly problematic to block and only one compound (CTS21166) has reached clinical testing so far. Conversely, several inhibitors of β-secretase, the protease that regulates the last metabolic step generating Aβ, have been identified, the most advanced being LY-450139 (semagacestat), presently in Phase III clinical development. Compounds that stimulate β-secretase, the enzyme responsible for the nonamyloidogenic metabolism of APP, are also being developed one of them, EHT-0202, has recently started a Phase II study. Furthermore, brain penetrant inhibitors of Aβ aggregation have been identified and one of such compounds, PBT-2, has produced encouraging neuropsychological results in a recently completed Phase II study. With all these anti-Aβ approaches in clinical testing, we will know in few years if the Av hypothesis of AD is correct.
Export Options
About this article
Cite this article as:
Frisardi V., Solfrizzi V., Imbimbo P. B., Capurso C., D'Introno A., Colacicco M. A., Vendemiale G., Seripa D., Pilotto A., Capurso A. and Panza F., Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid, Current Alzheimer Research 2010; 7 (1) . https://dx.doi.org/10.2174/156720510790274400
DOI https://dx.doi.org/10.2174/156720510790274400 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heart Failure in Minority Populations - Impediments to Optimal Treatment in Australian Aborigines
Current Cardiology Reviews Editorial [ Pain Guest Editors: Robert W. Gereau IV & Ferdinando Nicoletti ]
Current Neuropharmacology Impact of Ondansetron on Withdrawal Signs, Fentanyl Requirement and Pain Relief in Opioid-addicted Patients under General Anesthesia
Current Clinical Pharmacology The Effects of Age on Precision Pinch Force Control Across Five Days of Practice
Current Aging Science Temporal Expression of Mutant TDP-43 Correlates with Early Amyotrophic Lateral Sclerosis Phenotype and Motor Weakness
Current Neurovascular Research 3D QSAR Pharmacophore Modeling for c-Met Kinase Inhibitors
Medicinal Chemistry The Impact of Crystallographic Data for the Development of Machine Learning Models to Predict Protein-Ligand Binding Affinity
Current Medicinal Chemistry Oxidative Stress, Mitochondrial Abnormalities and Proteins Deposition: Multitarget Approaches in Alzheimer's Disease
Current Topics in Medicinal Chemistry Proinflammatory Cytokines and Sickness Behavior in Rheumatic Diseases
Current Pharmaceutical Design Baicalein-Phospholipid Complex: A Novel Drug Delivery Technology for Phytotherapeutics
Current Drug Discovery Technologies Endogenous Regulation of Neural Stem Cells in the Adult Mammalian Brain
Central Nervous System Agents in Medicinal Chemistry Toward The Rational Design of Cell Fate Modifiers Notch Signaling as a Target for Novel Biopharmaceuticals
Current Pharmaceutical Biotechnology Polycystic Ovary Syndrome in Adolescents
Current Women`s Health Reviews Metabotropic Glutamate and Cannabinoid Receptor Crosstalk in Periaqueductal Grey Pain Processing
Current Neuropharmacology Hypothalamic Pituitary Adrenal Axis and Prolactin Abnormalities in Suicidal Behavior
CNS & Neurological Disorders - Drug Targets Capsaicin-Sensitive Nociceptive Innervation of the Dura Mater: Implications for the Pathomechanism of Headache
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry Synthesis, Cytotoxicity, Antioxidant and Antimicrobial Activity of Indole Based Novel Small Molecules
Letters in Drug Design & Discovery Lithium Restores Age-related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome
CNS & Neurological Disorders - Drug Targets Mitochondrial Dysfunctions in Bipolar Disorder: Effect of the Disease and Pharmacotherapy
CNS & Neurological Disorders - Drug Targets